Skip to main content
Erschienen in: Reactions Weekly 1/2022

01.06.2022 | Case report

Atezolizumab/bevacizumab

Anaphylaxis: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Gonzalez-Diaz SN, et al. Protocol for Desensitization to Atezolizumab and Bevacizumab After Severe Anaphylaxis in the Treatment of Lung Adenocarcinoma. Journal of Investigational Allergology and Clinical Immunology 31: 265-267, No. 3, 22 Jun 2021. Available from: URL: http://doi.org/10.18176/jiaci.0637 Gonzalez-Diaz SN, et al. Protocol for Desensitization to Atezolizumab and Bevacizumab After Severe Anaphylaxis in the Treatment of Lung Adenocarcinoma. Journal of Investigational Allergology and Clinical Immunology 31: 265-267, No. 3, 22 Jun 2021. Available from: URL: http://​doi.​org/​10.​18176/​jiaci.​0637
Metadaten
Titel
Atezolizumab/bevacizumab
Anaphylaxis: case report
Publikationsdatum
01.06.2022
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2022
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-022-16390-6

Weitere Artikel der Ausgabe 1/2022

Reactions Weekly 1/2022 Zur Ausgabe

Case report

Levamisole

Case report

Empagliflozin

Case report

Multiple drugs

Case report

Multiple drugs

Case report

Ibuprofen

Case report

Multiple drugs